Omnicell, Inc. (NASDAQ:OMCL) Shares Bought by 1620 Investment Advisors Inc.

1620 Investment Advisors Inc. lifted its position in Omnicell, Inc. (NASDAQ:OMCL) by 230.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,212 shares of the company’s stock after acquiring an additional 1,542 shares during the period. 1620 Investment Advisors Inc.’s holdings in Omnicell were worth $96,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. Arizona State Retirement System increased its holdings in Omnicell by 2.9% in the second quarter. Arizona State Retirement System now owns 12,853 shares of the company’s stock valued at $348,000 after buying an additional 357 shares in the last quarter. Texas Permanent School Fund Corp increased its position in shares of Omnicell by 1.2% in the first quarter. Texas Permanent School Fund Corp now owns 39,630 shares of the company’s stock valued at $1,158,000 after buying an additional 479 shares in the last quarter. Diversified Trust Co raised its stake in shares of Omnicell by 3.3% during the 2nd quarter. Diversified Trust Co now owns 15,364 shares of the company’s stock worth $416,000 after buying an additional 494 shares during the period. GAMMA Investing LLC lifted its position in shares of Omnicell by 78.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after buying an additional 553 shares in the last quarter. Finally, Louisiana State Employees Retirement System grew its stake in Omnicell by 2.7% in the 2nd quarter. Louisiana State Employees Retirement System now owns 23,100 shares of the company’s stock valued at $625,000 after acquiring an additional 600 shares during the period. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on OMCL. StockNews.com raised shares of Omnicell from a “hold” rating to a “buy” rating in a report on Saturday, October 19th. Wells Fargo & Company increased their target price on Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a report on Monday, October 14th. JPMorgan Chase & Co. boosted their price target on Omnicell from $26.00 to $37.00 and gave the stock a “neutral” rating in a research report on Friday, August 23rd. Benchmark reaffirmed a “buy” rating and set a $48.00 target price on shares of Omnicell in a research note on Wednesday, October 9th. Finally, Barclays raised shares of Omnicell from an “underweight” rating to an “equal weight” rating and upped their price objective for the company from $26.00 to $39.00 in a research note on Friday, August 2nd. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, Omnicell currently has an average rating of “Moderate Buy” and an average price target of $41.33.

Omnicell Stock Up 32.2 %

OMCL stock opened at $53.05 on Thursday. Omnicell, Inc. has a one year low of $25.12 and a one year high of $55.74. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.22 and a current ratio of 2.45. The firm has a market cap of $2.44 billion, a PE ratio of -115.33, a PEG ratio of 43.55 and a beta of 0.83. The firm’s 50 day moving average price is $43.14 and its 200-day moving average price is $35.07.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, August 1st. The company reported $0.51 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.37. The firm had revenue of $276.80 million during the quarter, compared to the consensus estimate of $254.41 million. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. The firm’s revenue for the quarter was down 7.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.29 EPS. On average, equities research analysts anticipate that Omnicell, Inc. will post 0.64 EPS for the current year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.